39.70

2.00% 0.78

Legend Biotech Corp Adr (LEGN)

Overview News Price History Option Chain Why LEGN Down? Discussions Forecast

Legend Biotech Corp Adr stock is traded at $39.70, with a volume of 1.00M. It is up +2.00% in the last 24 hours and up +14.51% over the past month. Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Previous Close:

$38.92

Open:

$39.44

24h Volume:

1.00M

Relative Volume:

0.77

Market Cap:

$7.28B

Revenue:

$520.18M

Net Income/Loss:

$-348.13M

P/E Ratio:

-20.68

EPS:

-1.92

Net Cash Flow:

$-176.18M

1W Performance:

+9.01%

1M Performance:

+14.51%

6M Performance:

-29.68%

1Y Performance:

-33.65%

1-Day Range:

$39.42

$40.00

1-Week Range:

$36.91

$40.00

52-Week Range:

$30.17

$70.13

Legend Biotech Corp Adr Stock (LEGN) Company Profile

Name

Legend Biotech Corp Adr

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

Address

Employee

1,800

Twitter

@LegendBiotech

Next Earnings Date

2024-11-12

Latest SEC Filings

LEGN's Discussions on Twitter

Compare LEGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LEGN Legend Biotech Corp Adr	39.70	7.28B	520.18M	-348.13M	-176.18M	-1.92
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-08-24	Initiated	Redburn Atlantic	Buy
Jun-17-24	Initiated	Truist	Buy
May-24-24	Reiterated	H.C. Wainwright	Buy
May-23-24	Initiated	Deutsche Bank	Buy
Apr-17-24	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Apr-03-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-24	Initiated	Raymond James	Outperform
Dec-19-23	Initiated	Scotiabank	Sector Perform
Nov-06-23	Initiated	Goldman	Buy
May-25-23	Initiated	William Blair	Mkt Perform
May-22-23	Initiated	Daiwa Securities	Buy
Mar-29-23	Initiated	H.C. Wainwright	Buy
Mar-24-23	Initiated	RBC Capital Mkts	Outperform
Dec-06-22	Initiated	UBS	Buy
Nov-02-22	Initiated	Evercore ISI	Outperform
Nov-01-22	Initiated	Cowen	Outperform
Oct-31-22	Initiated	Guggenheim	Neutral
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Mar-15-22	Initiated	Barclays	Overweight
Jan-31-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-21-21	Initiated	Piper Sandler	Overweight
May-18-21	Initiated	BTIG Research	Buy
Jul-01-20	Initiated	JP Morgan	Overweight
Jul-01-20	Initiated	Jefferies	Buy
Jun-30-20	Initiated	Morgan Stanley	Overweight

View All

Legend Biotech Corp Adr Stock (LEGN) Latest News

Feb 13, 2025

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? - Yahoo Finance

Feb 13, 2025

Feb 11, 2025

Market Momentum: Aptargroup Inc (ATR) Registers a 0.07 Increase, Closing at 143.28 - The Dwinnex

Feb 11, 2025

Feb 10, 2025